These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 21041914

  • 1. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.
    Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, Delfraissy JF.
    Antivir Ther; 2010; 15(7):993-1002. PubMed ID: 21041914
    [Abstract] [Full Text] [Related]

  • 2. Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.
    Gupta S, Lataillade M, Farber S, Kozal MJ.
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):87-92. PubMed ID: 19270153
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy of atazanavir in treatment-naive patients].
    Moreno S, Hernández B, Dronda F.
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [Abstract] [Full Text] [Related]

  • 6. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS, ARIES study team.
    AIDS; 2010 Aug 24; 24(13):2019-27. PubMed ID: 20613461
    [Abstract] [Full Text] [Related]

  • 7. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 24; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.
    Antivir Ther; 2006 Mar 24; 11(4):421-9. PubMed ID: 16856615
    [Abstract] [Full Text] [Related]

  • 10. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW, AIDS Clinical Trials Group 5201 Study Team.
    JAMA; 2006 Aug 16; 296(7):806-14. PubMed ID: 16905786
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients.
    Lambert-Niclot S, Machouf N, Peytavin G, Soulie C, Wirden M, Simon A, Murphy RL, Katlama C, Thomas R, Calvez V, Marcelin AG.
    HIV Med; 2010 Nov 16; 11(10):666-9. PubMed ID: 20497253
    [Abstract] [Full Text] [Related]

  • 12. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV, Hesse K, Amin J, Cooper DA.
    Antivir Ther; 2010 Nov 16; 15(7):1035-8. PubMed ID: 21041919
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A, Sawyer W.
    HIV Med; 2009 Oct 16; 10(9):527-35. PubMed ID: 19785663
    [Abstract] [Full Text] [Related]

  • 15. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.
    Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, Hoffmann M, Hirschel B.
    AIDS; 2007 Jun 19; 21(10):1309-15. PubMed ID: 17545707
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May 19; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

  • 19. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
    Rubio R, Serrano O, Carmena J, Asensi V, Echevarría S, Flores J, Ribera E, Zarraga M, Ocampo A, de la Fuente B, Sepúlveda MA, Mariño AI, Minguez C, Vicent R, Cartón JA, Moyano B, Esteban H, Mahillo B, Serrano L, González-García J, GESIDA 44/04 SIMPATAZ Study Group.
    HIV Med; 2010 Oct 01; 11(9):545-53. PubMed ID: 20345884
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B, Staccato Thailand Study Group.
    Antivir Ther; 2008 Oct 01; 13(3):375-80. PubMed ID: 18572750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.